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Abstract
The cancer of the vulva is a rare disease with a positive association to poor 
developing countries. However, the incidence of vulvar cancer in situ nearly 
doubled in the last two decades and remained relatively stable. The main reason 
for this increased incidence of vulvar intraepithelial neoplasia (VIN) in women 
younger than 45 years is due to changes in sexual behavior, first intercourse at early 
age, multiple sexual partners, and sexually transmitted diseases that were increas-
ing progressively. Furthermore, it is strongly associated with smoking and the 
increased incidence of HPV infection. The occurrence of early symptoms of VIN-
like pruritus vulvae, pain, and lichen sclerosus led to early diagnosis to perform the 
adequate treatment. VIN tends to appear multifocal, while most invasive cancers are 
unilateral located and appeared with well-circumscribed lesions.
Keywords: lichen sclerosus vulvae, atrophic and hypertrophic disorders, vulvae, 
psoriasis
1. Introduction
1. The all vulva consisting of the mons pubis, the labia majora and minora, the 
clitoris, and the vulval vestibule, is covered by keratinized squamous epithe-
lium as opposed to the vaginal mucosa covered by nonkeratinized epithelium 
of the same type. The labia majora carry hair and contain sebaceous and sweat 
glands. Embryologically, they correspond to the male scrotum. The lymph 
nodes of vulva drain to the external iliac lymph nodes via inguinal lymph 
nodes. The area is extremely vascular [1, 2].
2. After taking a detailed personal medical history regarding to hygiene tech-
niques focusing on the use of antibiotic ointments, antiseptics, topical anal-
gesics, lubricants should the gynecologist establish, whether the examining 
woman suffers from general skin conditions including dermatitis, psoriasis, 
lichen sclerosus, allergic contact dermatitis, or suspicious vulva disorders. It is 
commonly agreed that the rate of allergic dermatitis is high in combination to 
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vulvar symptoms [3]. During the examination, the clinician should carefully 
examine the vulva and pay attention to skin or mucosal color (erythema and 
intense red); texture can provide clues to correct diagnosis (e.g., slight hyper-
keratosis and thickened skin) existence of any lesions, which seems unusual for 
such macules, papules, or ulcers [4, 5]. Ulcers of vulva are diagnostically chal-
lenging due to variation in clinical morphology [4, 5]. The primary morphology 
is clinically relevant for identifying because it can significantly narrow the dif-
ferential diagnosis. Diagnosis of vulvar ulcers based solely on clinical findings 
is often inaccurate, in most cases depending on sexually transmitted infections, 
but the differential diagnosis can include also dermatoses, trauma, neoplasms, 
hormonal-induced ulcers, drug reactions, or ulcer of unknown etiology [6, 7].
Subsequent to the completion of detailed observation, the clinician can decide 
for the diagnosis, if additional tools are necessary like speculum examination, 
vulvoscopy, or dermoscopy. The benefit of vulvoscopy remains controversial [8]. 
The contribution of dermoscope is mainly for the evaluation of both pigmented and 
nonpigmented lesions, presence of scarring, and loss of architecture but required 
training to identified benign structures and suspicious, worrisome features. It is 
crucial to document the number, type, size, border characteristics, and depth of 
lesions, discharge if present, tenderness, and presence or absence of local lymph-
adenopathy, which could influence mode of treatment [9, 10]. Cultures should be 
taken if there is suspicion for an infection, and final genital biopsies were recom-
mended without to be prerequisite for the completion of the definitive diagnosis. It 
is an all common finding for a clinician to be frustrated by pathology report because 
it is sometimes difficult for the gynecologist due to inherent challenges to approach 
the obtaining tissue from the genitalia.
In 1976, Freidich classified skin disorders of the vulva into three categories: 
(a) hyperplastic dystrophy, (b) lichen sclerosus, and (c) dystrophy with or with-
out atypia. For example, the term of hyperplastic dystrophy was used to include 
completely different clinical features, such as psoriasis, chronic lichen planus, and 
Bowen’s disease [11].
Due to diagnostic problems resulting from this classification, in 1989, the 
International Society for the Study of Vulvar Diseases established a new terminol-
ogy, which has been maintained to date [12]. Nonneoplastic epithelial lesions 
were delineated as follows: (a) lichen sclerosus and atrophicus, (b) squamous cell 
hyperplasia (former hyperplastic dystrophy without atypia), and (c) other dis-
eases of vulva, a category in which various injuries occur, such as psoriasis, lichen 
planus, fungal infections, and condyloma acuminata. Since cytological atypia is 
found in this category, the damage is “changing” category and now belongs to the 
VIN classification [12].
2. Disorders of the vulva
2.1 Dermatopathies
“Dystrophy” of the vulva is an abnormality of the vulva epithelium. Epithelial 
growth may be hypoplastic, hyperplastic, or abnormal in some other way [13, 14].
2.1.1 Atrophic and hypertrophic disorders
Atrophic and hypertrophic disorders of the vulva come under the general 
term of dystrophies (formerly characterized as “precancerous” conditions). 
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The skin, depending on the damage, may be appeared as white, dry, and thin 
or thickened, while hyperkeratosis and decreased vasculature are histologically 
present [15]. These alterations are mainly attributed to estrogen deficiency and, 
to this end, are often observed after menopause. The disorders may extend to 
the vaginal entrance, the perineum, etc. Usually there is intense pruritus, and 
the scratching it entails may result in an interception to the continuity of the 
skin. In addition to pruritus, there may be a burning sensation and dyspareunia, 
especially if the damage (usually atrophy) extends to the vaginal entrance [15]. 
For the treatment of pruritus, anti-inflammatory creams and topical corticoste-
roids are used (about two times a day). Antibiotic treatment is also administered 
in a transfection. In the absence of symptomatic treatment with conservative 
treatment and very intense annoyances of the patient, a simple vulvectomy can 
be chosen as “final” solution provided that the patient has been informed about 
the fact that in the half of the cases, the disease can relapse despite the surgical 
procedure [15].
Because of the fact that these disorders may coexist with malignancy, careful 
monitoring of the patient is required, and in doubt, multiple biopsies are required 
to exclude intraepithelial neoplasia (vulvar intraepithelial neoplasia/VIN) or 
cancer. Biopsies are often subjected to vulvovaginal screening after a 1–2% acetic 
acid solution is applied. However, the likelihood of developing invasive cancer in 
the soil of previous lesions is low. Given that these situations are well known, their 
descriptive “encyclopedic” terminology (in brackets, in italics) is not mentioned in 
the narrower “gynecological” or histological sense [16–21].
These alterations include:
• Lichen sclerosus
• Scuamous cell hyperplasia
• Condyloma acuminata
• Psoriasis
• Lichen planus
• Mixed lichen sclerosus and atrophicus
The term dystrophic lesions of the vulva according to literature like writhing, 
leukoplakia, lichen sclerosus and atrophicus, it is preferable to not be used anymore 
[16, 20, 21].
2.1.1.1 Lichen sclerosus
“Lichen sclerosus” (LS) is a term used for a benign, chronic, progressive derma-
tological condition characterized by (intense) inflammation [22–25]. The epithe-
lium is getting thinner, and some characteristic dermatological changes appeared 
accompanied by itching and pain.
In general, lichen sclerosus appears in the skin of the genitalia. It was first 
described by Hallopeau and Darier at the end of the nineteenth century as a variety 
of lichen planus, which is not acceptable today. The term lichen sclerosus (and/
or atrophicus) should no longer be used, as forms of lichen sclerosus are not all 
atrophic. When there is coexistence of squamous cell hyperplasia, it is characterized 
as “mixed squamous cell hyperplasia and lichen sclerosus” [26–32].
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Lichen sclerosus is considered as the most common chronic lesion in vulva, 
referred to a chronic atrophy that usually observed after menopause. Clinically, 
vulva is glossy and dry, with no folds. The lesions are often symmetrical. Although 
the condition is observed over a wide range of ages, it has an increased incidence 
in women aged 50–59 years. Postmenopausal women and young girls are usually 
afflicted before menstruation. There is no clear justification. There is sufficient 
evidence of involvement of autoimmune mechanisms in the pathogenesis of lichen 
sclerosus. It is known that 21% of patients with lichen sclerosus also suffer from 
autoimmune disease more often than with thyroid disease. It is reported that 22% 
of patients with lichen sclerosus have an inherited history, and that 44% have one 
or more autoantibodies. Also, there is a correlation with HLA II antigens. There are 
studies associating inflammatory factors, e.g., Borrelia infection, with the develop-
ment of lichen sclerosus. It is also reported that there is overexpression of wild-type 
P53 protein in lichen sclerosus, which occupies areas adjacent to squamous cell 
carcinoma (SCC) in which HPV is not detected.
Typically, the rash of lichen sclerosus begins as white polygonal papules, which 
flock to plaques. Typically, candlesticks and/or clearly cracked plugs appear on 
the surface of the plate, and they are similar to attached nozzles. Over time, plugs 
and craters may disappear by dropping a smooth, often porcelain plaque, and they 
rarely show up. Thus, the skin appears white and thin, although it may be pres-
ent in SCH [26–32]. Originally, lichen sclerosus may have a bubbling consistency 
and is characterized by edema of the prepuce clitoris and telangiectasia of labia 
and purpura. Stretch marks appear mainly in the middle perineal line. Bullous 
lichen sclerosus is often accompanied by bleeding within the lesion, and the fillet 
can disappear. Later, labia minora and structures around clitoris disappeared too. 
The epithelium of the vagina and the cervix is not affected. However, there may 
be lesions in the forehead of the skin, which will lead to its constriction. Perianal 
lesions are described in 30% of cases [26–32].
Lichen sclerosus is a benign vulva condition associated to chronic and often 
progressive character with dermatologic location. Among the clinical findings 
are included marked inflammation, epithelial thinning, distinct dermal altera-
tions like pruritus, and pain by varying degrees. The described lesions appear 
most frequently in the labia minora, but the early disease course affects not the 
vulvar architecture. During the disease progresses, the following pathological 
signs may be possible to occur: sexual dysfunction, fissuring in perineal region 
and around the clitoris, distinction between labia majora and minora, edema 
from inflammation, purpural lesions, and excoriations ecchymoses given fragil-
ity of the affected skin region [5, 33]. The main symptom is pruritus. Pain occurs 
if there are corrosions and stretch marks. Itching is intense during the night and 
may be so intense that it stops sleeping. Discomfort occurs when there is erosion, 
stretch marks, or narrowing of vaginal orifice [26–32]. Some women are asymp-
tomatic, and LS is a random finding. Most of them had active childhood disease, 
which resulted in skin atrophy without symptomatology. Occasionally, hyper-
keratosis and ecchymosis occur, which should be treated [26–32]. In childhood, 
the lesions are similar to adult lesions. But the ecchymosis may protrude and can 
be so intense that it leads us wrongly to the suspicion of sexual abuse. The diag-
nosis in most patients is indicated by the clinical picture, but its confirmation by 
histopathological examination is considered necessary. LS should be differenti-
ated from lichen planus, vaginal pemphigoid, psoriasis, VIN, and SCC, and this 
is done by biopsy under colposcopic control. Ulcers, nodules, and granulomas 
should be controlled to exclude malignancy. The formation of hyperkeratotic 
plaques and erosions, which do not exist despite the applied treatment, suspects 
malignant transformation [26–32, 34].
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Histologically, there is a decrease in subcutaneous fat, atrophy of all skin layers, 
and destruction of elastic tissue. The dermis is of some degree vitreous degenera-
tion and round cell collections [35–37]. Typical histological findings are also 
including a thinned epidermis with areas hyperkeratosis, acanthosis, a broad band 
of homogenized collagen under the dermo-epidermal ligament, and lymphocyte 
infiltration under the homogenate area [33, 38–39].
Few patients have thickening of the epidermis, and these are those who have 
not been responding to LS and who are at increased risk of developing SCC. Due to 
the frequent association of LS with autoimmune diseases, the appropriate control 
should be performed. In particular, the possibility of autoimmune thyroid disease 
should be investigated [26–32, 34].
Squamous cell carcinoma (SCC) in women with LS is a common malignancy 
described. There are also reports of basal cell carcinoma and melanoma. The risk 
of developing SCC is about 5%. However, histopathologic examination in woman 
with lichen sclerosus during follow-up revealed squamous cell carcinoma. The role 
of HPV as a causative agent in malignant transformation is not entirely clear. There 
are studies suggesting the existence of two types of SCC: one type occurs in older 
patients with chronic LS disease and the other type is in younger women without LS 
but with proven infection by oncogenic HPV types. Although there is no evidence 
of the role of HPV as a causative agent in the development of SCC on LS, there is the 
theoretical risk of developing SCC from the topical use of corticosteroids, which 
may promote the development of HPV oncogenic strains, since it was found that in 
20% of cases LS, there may be HPV infection [40–43]. More recent reports support 
the strong relationship of vulvar invasive squamous cell carcinoma and LS, so that 
lichen sclerosus is considered as precancerous damage [33]. It is not uncommon 
for women with carcinoma of vulva from squamous cells to also have undiagnosed 
lichen sclerosis, which may also be asymptomatic [33, 38].
The role of midwives, especially those who have increased initiatives due to their 
position (e.g., the one who works in the Center of Health), is very important to properly 
direct these postmenopausal women. It is well known that empirical use of ointments 
in precancerous or cancerous lesions of the vulva delays proper treatment and requires a 
high degree of suspicion of the doctor and midwife for malignant malignancy [33, 38].
There is no universally accepted treatment for women with lichen sclerosus. 
The treatment includes education and support, change of behavior to ensure good 
pudding hygiene, medication, and, in a small proportion of cases, surgery or pho-
tochemotherapy. The medical treatment of the condition includes the topical use of 
corticosteroids, such as clobetasol [44–47]. The major importance of LS treatment 
is proved by the fact that about 80% of invasive squamous cell carcinoma (SCC) of 
the vulva in elderly patients was associated with untreated, long-term conditions of 
lichen sclerosus (the final stage of the vicious cycle of itching-scratching-itching). 
Generally, the management should perform in twofold.
The first step aims to resolve LS symptoms, vulvar, and vaginal pain.
The second step’s goal is to reduce the disease signs like hyperkeratosis fissuring 
echymoses [44–47].
2.1.1.2 Squamous cell hyperplasia
The oldest term leukoplakia (“chronic inflammatory disease of the mucosa 
which results in keratinization of the epithelium and in the formation of white 
spots”) is still reported today. The disorder is characterized by white, tough, and 
overwhelmed, hyperkeratotic “plaques” of the vulvar epidermis, and a disorder of 
“hormonal homeostasis” in its etiology. Histologically, squamous cell hyperplasia is 
observed (Figures 1 and 2).
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This chronic and recurrent condition may occur at any age but is more common 
in older patients and usually manifests with pruritus. Less often, it occurs with 
dyspareunia or pain. It is an autoimmune condition and is associated with other 
autoimmune diseases such as malignant anemia, thyroid disease, diabetes mellitus, 
systemic lupus erythematosus, primary biliary cirrhosis, and bullous pemphigoid. 
Histologically, the skin appears thin with loss of the crevices found between the 
nipples. Surface skin is vitrified, and a set of chronic inflammatory cells is observed 
beneath it [48–53].
Clinically, the skin appears white, thin, and corrugated but may be overlapped 
and keratinized, if there is coexistence of squamous cell hyperplasia. There may 
also be symphysis of the clitoris or the vulva. The diagnosis is made by biopsy. 
Lichen sclerosus is a nonneoplastic condition but can coexist with vulvar intraepi-
thelial neoplasia, while there is correlation with invasive squamous cell carcinoma 
of the vulva in 2–5% of cases. This is describing the reason why possible long-term 
monitoring is required every 6–12 months [26–32].
Treatment is required, especially if the condition is symptomatic, and a strong 
local topical steroid cream (e.g., Dermovate per 12-hour period) is usually used, 
which is gradually replaced by a milder formulation (e.g., hydrocortisone per hour, 
24 h or less) as the symptoms require. Fluorinated corticosteroids or testosterone 
Figure 1. 
VIN lesions are usually characterized by a change in color on the skin of the vulva. They are usually white and/
or gray.
Figure 2. 
VIN lesions: The rarities are lesions in red and brown. Their surface may be flat or abnormal.
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ointment may also be helpful. Vulvectomy has no position in this case, as the recur-
rence rate after surgery is about 50% [26–32].
2.1.1.3 Psoriasis
Psoriasis is manifested as dry, red, and papular rash, which is usually clearly 
circumscribed and extends to the thighs. Diagnosis occurs easily when bleeding is 
observed during the removal of classic silver-like scars. It may be difficult to differenti-
ate psoriasis from candida infection or dermatitis because the vulva is very often fluid. 
Candida infection should be ruled out. The lesions can be treated locally with coal tar 
preparations, ultraviolet maize, steroid creams, or other suitable drugs [54–56].
2.1.1.4 Lichen planus
It is a chronic papular rash with a bluish hue, which is located in the vulva and 
the bendable surfaces. It may be appeared in other areas like the mucous membrane 
of the oral cavity, and the diagnosis is enhanced by finding other lesions. Oral 
lesions precede genital lesions in one-third and simultaneously appear in half of 
women affected from the disease. After the vulva should be a vaginal examination, 
the walls of the vaginal may have following pathological abnormalities: erythema 
erosions and bleeding friable tissue. It is usually idiopathic but can also be related 
to medications. The treatment includes use of strong steroids locally or ultraviolet 
light, and the disease tends to subside within the next 2 years. Surgery removal 
should be avoided [57–62].
2.1.2 Others: vitiligo, intertrigo, aphthae
2.1.2.1 Vitiligo
The lesions of this disease can appear anywhere on the body with a predilec-
tion in the genital area. It can be confused with LS, associated to lack the classical 
signs of inflammation, possible coexistence with LS based on autoimmunogenity. 
In contrast to LS, which has predilection for hypoostrogenic states, vitiligo can be 
appeared at any age. No skin biopsies are necessary. Autoimmune thyroid disease 
is associated to vitiligo. Treatment includes administration of topical steroids and 
vitamins D, E, C, and B12. Surgery remains a viable option in unresponsive local-
ized disease to conventional therapies [63–71].
2.1.2.2 Apthtae
They are vulva disorder associated to pain. Shallow ulcers most commonly 
occur on the oral mucosa and less commonly on the genital mucosa. The reasons 
are uncertain, and risk factors include stress, infections, hormonal factors, vitamin 
deficiency, and family history. The diagnosis result from exclusion of various 
genital ulcers causing in most cases in assumption of sexually transmitted infec-
tion. Aphthosis appears in simple and rare complex form, and the recurrence rate is 
about 20% of the general population. For the treatment, it is important to educate 
the patients to conform in skin and wound care and administration of topical 
corticosteroid propionate ointment in cases of complex aphthosis [63–71]. Apthae 
should differentiate from Behcet syndrome, a disorder that causes inflammation 
of the blood vessels throughout the body, and could affect the vuvla causing open 
sores in the vulva. Furthermore, vulva aphthous ulcers could appear in patients 
with HIV infection, Chrohn disease, and ulcerative colitis.
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2.1.2.3 Intertrigo combined with candida infection
Intertrigo is a wet inflammatory dermatitis, which can occur on any fold of the 
body because of the irritation of the exposed skin surfaces from friction between 
them. This is more likely to occur in women who are overweight but also in those 
who wear tight clothing.
The skin is painful, often red and flaky, showing wetness and stretch marks. 
Weight loss, local hygiene, and local exposure to air, such as the use of socks and 
cotton lingerie instead of synthetic underwear, should be envisioned. Powders (e.g., 
talc), astringents (e.g., zinc), or blocking agents in the area may also help.
Candida usually complicates intertrigo and should be treated as described according 
to clinical practice guidelines for the management of candidiasis [56, 57]. In order to 
relief the inflammation, since there is no candida infection, steroid creams may be used.
2.1.3 Allergic/irritant dermatitis
The skin of the vulva, and especially the opening of vagina, is often affected by 
dermatitis. Dermatitis can be irritating (nonimmune) or actually allergic (immune-
induced). Chemicals that cause skin hypersensitivity include, but are not limited 
to, cosmetics, perfumes, contraceptive lubricants, sprays, and vaginal washings. 
Detergents, dyes, softeners, bleaches, soaps, and bleach used to clean the under-
wear can also cause irritation. In severe cases, hypersensitivity may occur in topical 
application of anesthetic creams, as well as steroid preparations.
Women with contact dermatitis have an overgrowth inflamed vulva with 
eczema characters, and patch tests can reveal local irritants. Temporary relief can be 
achieved with lubricants of the vulva (e.g., Emulsiderm in a daily bath), softeners 
(e.g., local water creams), and topical corticosteroids (e.g., monthly treatment with 
Dermovate topical application). As before, nonresponsive lesions need biopsy to 
confirm the diagnosis [72–75].
2.2 Pruritus
The term pruritus describes an intense feeling of itching. It is more common 
in women over the age of 40 years, and symptoms are getting worse by stress or 
depression. There are many causes of itching.
Biopsy may be necessary for diagnosis, as well as patch tests may be also helpful. 
If no cause is found, it may be worth considering the possibility of previous sexual 
abuse or psychosocial problems.
It is important to stop the vicious cycle of irritation/itching cycle that is using 
strong local steroids for a short time in order to reduce the local inflammation induced 
by scratching. Applying strong steroid ointment daily for 3 weeks followed by 1% 
hydrocortisone cream once a day is useful, as well as soap substitutes (e.g., Oilatum).
Irritants, cosmetics added to bath, and synthetic pantyhose, as well as soap 
substitutes, should be avoided, and comfortable cotton underwear should be used. 
The area should be gently dry (e.g., with a hairdryer). Antihistamines can also help. 
If depression coexists, it may require treatment [76–84].Reasons of vaginal pruritus
Infection (candida, luteum, filamentous worms)
Eczema
Dermatitis (patch tests)
Irritation due to vaginal excretion
Lichen sclerosus
Lichen planus
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Vulvar intraepithelial neoplasia (VIN)
Vulvar cancer
Systematic diseases (diabetes mellitus, ureamia, or liver deficiency)
Psychogenic [82–84]
2.3 Vulvar intraepithelial neoplasia (VIN)
The term VIN was proposed to include dysplastic lesions and vulvar squamous 
in situ cancer and replace terms such as: (a) Bowen’s disease; (b) Bowen’s papilloma; 
and (c) dystrophy with atypia.
Depending on the degree of maturation of the neoplastic epithelium and the 
extent of atypia, three VIN classes, from I to III, are defined just like in CIN.
2.3.1 New terminology: previous terminology
VIΝ I: mild dysplasia
VIΝ II: moderate dysplasia
VIN III: Toy Bowen’s disease, severe dysplasia
Squamous cell carcinoma in situ, erythroplasia of Queyrat
The lesion is characterized as VIN I when the cellular abnormalities, in compari-
son with absence of layout, are limited to the lower one-third of the vulvar squa-
mous epithelium, VIN II when the abnormalities extend to the middle third of the 
epithelium, VIN III when they extend to the upper third of the epithelium, and CIS 
when lesions occupy all the epithelial layers. Approximately 40% of women present 
without accompanied symptoms and in the rest cases a background of inflamma-
tory skin disease in the majority being lichen sclerosus exist.
The disease is not characterized as invasive carcinoma as long as the basal lamina 
remains intact [72–75].
2.3.2 Risk factors VIN
Common point: VIN is part of a total of epithelial changes in the woman's 
inferior genital system and may coexist (at least 15–20%). In particular, if there are 
acuminate warts in the vulva, the rate for CIN lesions is almost 50%.
2.3.3 Risk factors
1. Early onset of sexual activity
2. Switching (multiple) sexual partners
3. Immune system weakness
4. Cross-reaction or coexistence of high-risk HPV subtypes
5. Smoking, alcohol, and unbalanced diet
6. HPV infection
7. HSV-2 infection
8. Chronic irritation of the vulva
9. Warts
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2.3.4 Biological behavior and prognosis VIN and CIN
In most VIN cases, instead of CIN, the damage is high risk. It is also uncommon 
to diagnose just VIN I lesion.
VIN:
• increased incidence in last two decades
• average age of development 30 years
• risk of progression to invasive cancer increased in women of the fifth decade (20%)
• the recession is twice as likely as invasion.
It is more common in women of 20–30 years, while VIN III in the fourth decade 
whereas invasive cancer mainly in the fifth decade [32, 34, 40].
2.3.5 Clinical finding and diagnose of VIN and CIN
VIN instead of CIN is not appeared during colposcopy with abnormal vasculation 
and mosaicism, but in the form of subtracted white or red plaques with clear borders.
Due to keratinization of the surface layer, in case of VIN, the cytological evalua-
tion is more difficult.
VIΝ: itching, burning sensation, pain, single, or multifocal lesions (40%)
CIN: there are usually no symptoms or findings, single, or multifocal lesions
VIN: lesions often situated in the inner lips of vagina and the perineum
CIN: lesions frequently cited in the transformation zone
3 Basic principles in treatment of depigmentation disorders of the vulva
3.1 Clobetazole (Butavate*)
Treatment of choice is the topical administration of clobetazole, which blocks 
mitosis and induces synthesis of proteins reducing inflammatory response. It is also 
believed that it affects Ki67 as well as promotes p53 expression.
For those cases that diagnosed for the first time, it is recommended to apply 
once daily for 4 weeks, then every second day for 4 more weeks and during the 
third month of treatment, twice a week (once a day is based on pharmacokinetic 
studies). If symptoms reappear, the minimal clobetazole dose in which disease was 
controlled is administered.
A 30 g tube should be used for 12 weeks, and then, the original is reconsidered. 
If treatment is effective, hyperkeratosis, bruising, erosions, and stretch marks will 
disappear, but atrophy and color change still remain.
Clobetazole is continued as needed. Most patients usually need 30–60 g per year. 
If therapy is complete, no further treatment is needed, but other patients will have 
relapses and should continue to receive treatment [72–75].
An alternative option is triamcinolone ointments.
3.2 Testosterone and other hormones
Nowadays, estrogens or testosterone creams have no place in the LS treatment. 
Also recent studies have shown that testosterone is less effective than clobetazole 
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and has same effectiveness with petrolatum, the excipient used to make testoster-
one ointment.
3.3 Progesterone
It is referred to be extremely effective. It is prepared by mixing 400 mg proges-
terone oil with 4 oz Aqua-for. It is prescribed twice a day.
3.4 Retinoids
They are mainly used in the complicated LS on failure of corticoid treatment. It 
is considered that they reduce the degradation of the connective tissue.
3.4.1 Acitrecine (Nco-Tigason*)
Acitrecine (Nco-Tigason*) 25 or 50 mg/24 h per os in a single dose until symp-
tom remission and continue 25–50 mg/24 hours go per os. The treatment stops 
when the lesions fall back.
3.4.2 Isotretinoin (Roaccutan*, Accurane*)
Isotretinoin (Roaccutan*, Accurane*) synthetic 13 is isomer of tretinoin. It reduces 
sebaceous gland size and sebum production and inhibits abnormal keratinization. The 
dose is 0.5–1 mg/kg/24 hours, and the duration of treatment is 4–6 months.
Topical administration of retinoids is not recommended due to the local irrita-
tion they cause.
Close attention should be paid to per os administration of retinoids to adolescents 
due to the teratogenicity they cause and is recommended avoidance of pregnancy for 
2 months (isotretinoin) and 3 years (acitretin) at the end of the treatment [72–75].
3.5 Other medications
Positive results from the administration of potassium para-aminobenzoate, as well as 
psoralen with UVA therapy, stanozolol, antimalarials, antihistamines (e.g. oxatomide), 
and various antibiotics (possible cause or infection by Borrelia), were also observed.
3.6 Surgical treatment
In uncomplicated forms of LS, there is no evidence of removal of vulvar tissue. 
Surgical treatment should be applied exclusively in case of malignant transforma-
tion and recurrent forms.
When there is a narrowing of the opening of vagina, perineoplasty is performed, 
which improves dyspareunia in 90% of cases and improves the quality of sexual life 
in 86% of cases.
Simple vulvectomy should not be preferred because the symptoms do not always 
disappear, the signs reappear, and the likelihood of malignant transformation 
persists. Also, the operation creates many psychosocial problems.
3.7 Alternative treatment
Positive results are reported with LASER ablation treatment, which is applied 
with LASER CO, 1–2 mm deep with complete healing 6 weeks after surgery and low 
relapse rates. It is considered a method of nonresponse to other forms of treatment.
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Photodynamic therapy (topical application of the 5-aminolevulinic acid pho-
tosensitizer and exposure to argon laser light for 1–2 alphas in 1–3 sessions) is also 
used with very good results.
3.8 General considerations for patients during treatment
Patients with LS have thin skin, which is not considered a “satisfactory” barrier to 
the loss of moisture, and it would be a failure not to mention some general measures.
1. Excessive drying after bathing should be avoided.
2. Gentle moisturizing products such as, e.g., Vaseline should be used to improve 
the moisture of the affected skin.
3. Good hygiene, avoidance of irritants and allergens, use of cotton lingerie, and 
avoidance of tight and hot clothes.
A lesion that resides in the vulva or in the vaginal opening and continues after the 
skin lesion is absent is secondary to a sensory disorder. This pain does not correspond 
to topical administration of corticosteroids. A 5% xylocaine ointment is therapeutically 
administered; on failure, administration of amitriptyline is recommended [72–75].
3.9 Failure of treatment
On unsuccessful treatment with corticosteroids, the following should be checked: 
patient compliance, misdiagnosis or coexistence of other disease entities, contact 
dermatitis, secondary candidiasis, VIN, SCC, psoriasis, or pemphigoid vulgaris.
If the symptoms persist after the medical repair of the damage, it is a secondary 
sensory disorder.
3.10 Follow-up
The risk of malignant transformation of LS is very small. Even if malignant trans-
formation occurs, the progression of the disease is slow. However, patients should be 
screened at the end of the first trimester of treatment after 6 months and then yearly.
One-month follow-up requires patients with a poor response to corticosteroid 
therapy, and they are usually those in whom squamous cell hyperplasia coexists and 
are therefore susceptible to malignant transformation.
4. Conclusion
Vulva pathology is varied. Between all the described lesions, precancer condi-
tions should be recognized early in order to stop the evolution. Strong dermocor-
ticoids are the major local treatment on many vulvae chronic diseases. In specific 
conditions, local immune modulators or laser are necessary.
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